【摘要】 目的分析国产与进口氯吡格雷在冠心病治疗中的疗效,并进行药物经济学分析,为临床上药物选择提供试验依据。方法将84例患者随机分为波利维组(进口)和泰嘉组(国产),对比分析两组患者的临床疗效、不良反应及治疗费用。结果随访1年期内,其主要心血管不良事件(MACE)发生率分别为波利维组2.38%(1/42),泰嘉组4.76%(2/42),且两组间临床疗效比较,差异无统计学意义(P=0.557)。但泰嘉组的治疗费用〔(4 948.3±1 199.4)元〕明显低于波利维组〔(7 986.3±980.4)元〕,两组比较,差异有统计学意义(t=12.71,P<0.01)。两组均存在上腹部不适4例以及皮疹2例。结论泰嘉组和波利维组在治疗效果、不良反应方面基本相同,泰嘉组的治疗费用明显低于波利维组;泰嘉可代替波利维用于冠心病的抗血小板治疗。更多还原

【Abstract】 Objective To compare the pharmaceutical efficiency and cost between Plavix and Taijia in treating coronary heart disease(CHD),with an attempt to provide guidance for the clinical selection of these two drugs.Methods Totally 84 CHD patients were randomly assigned to Plavix group(n=42) and Taijia group(n=42) for antiplatelet therapy.The clinic efficacy,side effects,and costs of these two clopidogrel bisulfate drugs were compared.Results During the 1-year follow-up,the incidence of major adverse cardiac event(MACE) was 2.38% in Plavix group and 4.76% in Taijia group(P=0.557).However,the mean treatment cost in Taijia group [(4 948.3±1 199.4) Yuan] was significantly lower than that in Plavix group [(7 986.3±980.4) Yuan](t=12.71,P<0.01).In both groups,four patients experienced upper abdominal discomfort and two had skin rash.Conclusion Taijia has equally good effectiveness and similiar side effects as Plavix,but with remarkably lower cost.Therefore,Taijia can be used as an alternative drug for Plavix in treating CHD.更多还原